Kornimate/medical-research-clean huggingface dataset:
network pharmacology was applied to explore the mechanism of remimazolam applied in general anesthesia for gynecological surgeries

Conditions: Gynecological Disease

Summary: to explore the related mechanisms by which remimazolam regulates hemodynamic stability, inflammatory factors and the immune system in patients undergoing general anesthesia for gynecological surgeries.

①clinical effect evaluation of remimazolam 1. compare the hemodynamic stability (heart rate, mean arterial pressure, blood oxygen saturation), anesthesia efficiency (induction time, recovery time), and safety (incidence of adverse reactions such as hypotension, hypoxemia, and injection pain) of remimazolam alone, propofol alone, and their combination in general anesthesia for gynecological surgeries. 2. clarify the optimal dose range of remimazolam and its synergistic effect with propofol, and optimize the anesthetic medication regimen. * the regulatory effect of remimazolam on the inflammation-immune axis and oxidative stress detect the dynamic changes of serum inflammatory factors (il-6, il-10, tnf-α), immune indicators (cd3+, cd4+, cd4+/cd8+) and oxidative stress markers (sod, mda) of patients before and after the operation, and analyze the regulatory effect of remimazolam on the above indicators.

Eligibility criteria:
inclusion criteria: 1. the patient or their family members sign the informed consent form 2. age: 18-64 years old, bmi: 18-30kg/m2 3. asa grade ⅰ or ⅱ 4. patients undergoing gynecological surgeries (laparoscopic total hysterectomy, adnexectomy and myomectomy) exclusion criteria: 1. people who are allergic to remimazolam or benzodiazepinesthyroid disease 2. long-term use of benzodiazepines 3. pregnancy or lactation 4. have a history of drug abuse or alcoholism 5. patients with contraindications for surgery 6. patients with hypertension (clinically diagnosed with hypertension) and patients with coronary heart disease (with typical angina pectoris symptoms and excluding aortic valve lesions, with a clear history of old myocardial infarction, with a clear history of acute myocardial infarction, and cag finding coronary artery stenosis greater than or equal to 70%) 7. patients with arrhythmia, heart failure, renal failure, and those who have recently taken cardiovascular active drugs 8. endocrine disorders such as hyperthyroidism and pheochromocytoma that may affect the hemodynamic level of the body 9. patients with ketoacidosis and lactic acidosis 10. abnormal liver function, alt\> three times the upper limit of the normal value; 11. renal failure (serum creatinine \>3mg/dl or creatinine clearance rate \<30ml/min) 12. patients who have been using sedatives or antidepressants for a long time, or have a history of alcohol abuse or drug dependence 13. asthma or reactive airway diseases 14. combined with underlying cognitive function abnormalities 15. exclusion criteria for research subjects 16. those who were mistakenly included without meeting the inclusion criteria 17. those who experienced adverse events such as shock, severe hypotension and severe arrhythmia during the operation

Keywords: remimazolam propofol gynecological disease
a randomized controlled trial comparing imipenem and tigecycline versus imipenem and tigecycline with gm-csf for the management of spontaneous bacterial peritonitis presenting with septic shock.

Conditions: Spontaneous Bacterial Peritonitis

Summary: study population: a total of 90 consecutive patients of decompensated cirrhosis of any etiology, presenting to the institute of liver and biliary sciences with sbp with septic shock will be included. study design: randomized controlled trial study period: august 2019 to december 2021. sample size: assuming that the response rate is 90% with gm-csf and 60% without gm-csf after day 5. with alpha 5 and power 80,we need to enroll 76 cases (38 cases with each). further assuming 20 % drop-out due to various reasons, it was decided to enroll 90 cases randomly allocated into two groups (i.e., 45 in each) by block randomization method by taking block size as 6. so for the present study, it was decided to enroll 90 cases in all. group a will be given imipenem and tigecycline. patients with recent hospitalisation will be given colistin in addition. group b will be given: to another group we will give imipenem and tigecycline and gmcsf.patients with recent hospitalisation will be given colistin in addition. the dose of antibiotic will be given at dosage inj imipenem 1gm i.v. tds inj tigecycline 100mg stat f/b 50mg i.v. od inj gm-csf 500mcg s.c. od inj colistin 9 miu i.v. stat f/b 4.5 miu i.v. bd monitoring and assessment at the baseline, all patients will undergo investigational evaluation as described daily monitoring of following parameters: * haemoglobin, * total peripheral leucocyte counts, * platelet counts, * renal function tests * liver function tests and * chest x rays will be undertaken * ascitic fluid analysis will be done on day 0, day 2 and day 5 stopping rule:if the patient develops a tlc of more than 50,000, the dose of the gm csf will be reduced to half and the treatment continued. if, even after the reduction, the tlc rises to more than 50,000, then the treatment will be stopped and the patient excluded. expected outcome of the project: addition of gm-csf to standard antibiotic regimen helps resolve sbp and improves outcome in decompensated liver cirrhotic patients.


Eligibility criteria:
inclusion criteria: 1. spontaneous bacterial peritonitis (sbp) with shock in a cirrhotic 2. hospital acquired sbp with shock 3. difficult to treat sbp exclusion criteria: 1. refractory shock 2. cardiac comorbidities (known coronary artery disease) 3. chronic kidney disease on maintenance hemodialysis 4. \< 18 years. 5. advanced hepatocellular carcinoma 6. post liver transplant 7. hiv + ve, immunosuppressive therapy
guided imagery training and self-referential processing

Conditions: Depression; Negative Thoughts

Summary: the purpose of this study is to examine the efficacy of a guided imagery paradigm for reducing negative ways of thinking about the self. there will be at least 60 participants enrolled at the university of texas at austin. participants will be randomly selected to receive one of two types of trainings, each over the course of two weeks. participants will undergo the training exercises at home. the training exercises will help them to think differently about themselves. participants will be able to determine if they are eligible, and then participate, by filling out a screening questionnaire online.

this study uses a randomized controlled trial to compare two types of guided imagery. one intervention is an active intervention; the other is intended to be inert. these interventions were developed based on extensive research indicating the efficacy of using imagery in depression, and a perceived lack of treatments targeting biased self-referential processing. this protocol aims to develop a novel intervention which can be used on its own or as an adjunct to existing treatments. common treatments for major depressive disorder (mdd) are diffuse; this paradigm instead aims to specifically target negative self-schema, a part of the cognitive model of mdd. this study focuses on participants with elevated depressive symptoms.

Eligibility criteria:
inclusion criteria: * willing and able to provide informed consent * elevated depressive symptoms -- i.e., a score above a 13 on the center for epidemiologic studies depression scale (cesd) exclusion criteria: * n/a

Keywords: guided imagery
predictors of hfnc failure in patients with ahrf using echocardiography parameters

Conditions: Acute Hypoxemic Respiratory Failure

Summary: right ventricular dysfunction (rvd) and right ventricular-pulmonary arterial (rv-pa) uncoupling detected by transthoracic echocardiography (tte) in acute respiratory distress syndrome (ards) are associated with poor survival. early detection of rvd and rv-pa uncoupling in patients with acute hypoxemic respiratory failure (ahrf) may be indicative of worsening and decompensating pulmonary condition which may require escalation of respiratory support. the use of tte parameters in predicting high-flow nasal cannula (hfnc) failure has not been previously studied. the objective of this study is to identify predictors of hfnc failure by tte and to compare its performance with the well-established rox index.


Eligibility criteria:
inclusion criteria: * age ≧ 18; and * acute hypoxemic respiratory failure (ahrf), defined by respiratory rate of greater than 25 breaths per minute and a ratio of the pao2 to the fraction of inspired oxygen (pao2 / fio2) of less than 300, and use of accessory muscles of respiration or paradoxical abdominal motion; and * required ventilatory support with high-flow nasal cannula (hfnc) exclusion criteria: * patients suffering from hypercapnic respiratory failure; or * ahrf secondary to conditions that are indicated for non-invasive ventilation (niv) (e.g. acute exacerbation of copd, cardiogenic pulmonary edema); or * use of niv or invasive mechanical ventilation (imv) prior to hfnc initiation; or * patients with imminent need for endotracheal intubation and invasive mechanical ventilation (imv); or * patients with known or suspected diaphragm paralysis; or * pregnancy; or * patients with abdominal compartment syndrome; or * use of hfnc for more than 12 hours prior to icu admission; or * patients with suboptimal echocardiographic image quality for data processing; or

Keywords: echocardiography acute hypoxemic respiratory failure high flow nasal cannula
the drug-drug interaction of sp2086 and metformin

Conditions: Type 2 Diabetes

Summary: this is an open single and self-control study,planning to recruit 24 cases of healthy male volunteers.in the study,subjects were given sp2086 and metformin,and collects blood samples before and after medcine.the purpose is to evaluate the drug interaction between sp2086 and metformin.


Eligibility criteria:
inclusion criteria: * healthy volunteers with a body mass index (bmi, a measure of a person's weight in relation to height) between 19 and 26 kg/m2,weight among of 50-100kg. * willing to using contraception during the study and after the 6 months. exclusion criteria: * history of diabetes * history of heart failure or renal insufficiency * urinary tract infections, or vulvovaginal mycotic infections * history of or current clinically significant medical illness as determined by the investigator * history of clinically significant allergies, especially known hypersensitivity or intolerance to lactose * known allergy to sp2086 or metformin or any of the excipients of the formulation of sp2086 or metformin
personalized spine study group (pssg) registry

Conditions: Scoliosis; Adolescence; Degenerative Disc Disease; Spinal Fusion; Kyphoscoliosis; Pseudoarthrosis of Spine; Spinal Stenosis; Kyphoses, Scheuermann

Summary: the primary objective of the study is a data collection initiative. the study will collect clinical and radiographic outcomes of patients implanted with patient specific rods. the secondary objective is to collect clinical and radiographic outcomes of patients with hardware as a control cohort to the patient-specific rods.

the registry follows patient during their standard of care visits. during a standard of care visit, a study subject will be required to answer questions about themselves and fill out patient reported outcome questionnaires. spinopelvic measurements will be collect from standard of care x-rays. this registry is observational only used to address patient outcomes sagittal profile through the pre-operative, plan and post-operative events. rod effectiveness in conjunction with other surgical implants by fusion assessment and sagittal alignment measurements. patient outcomes in subgroups defined by surgery performed, comorbidities, radiographic measurement, or other outcome variables. rod curvature maintenance during the follow-up period. better understanding of the post-operative risks and complications from the pre-operative condition.

Eligibility criteria:
inclusion criteria: * patient has been/ will be operated and instrumented with patient-specific rod or spine hardware (control cohort) * patient able to consent or assent exclusion criteria: * patient unable to sign an informed consent form * patient unable to complete a self-administered questionnaire * patient is pregnant or planning on becoming pregnant during the duration of their study participation * patient is older than 85 * patient is younger than 10
study to evaluate the impact of early initiation of biological treatment with ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: this study is to evaluate available data in iraqi patients with ankylosing spondylitis on enbrel treatment with regards to the impact of early treatment using data from the baghdad teaching hospital registry


Eligibility criteria:
inclusion criteria: * diagnosed as patients. * 18 years old * did not receive previous biological treatment for any reason exclusion criteria: * patients previously or currently treated with other biological therapies. * use of etanercept for less than 1 year duration.
safety and efficacy of ticagrelor versus clopidogrel in asian/korean patients with acute coronary syndromes intended for invasive management

Conditions: Acute Coronary Syndrome; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Angina Pectoris

Summary: the purpose of this study is to assess safety and efficacy of ticagrelor versus clopidogrel in asian/korean patients with acute coronary syndromes intended for invasive management.


Eligibility criteria:
inclusion criteria: * age 18 and more * index event of non-st or st segment elevation acs * provision of signed informed consent exclusion criteria: * hypersensitivity to aspirin or ticagrelor * oral anticoagulation therapy that cannot be stopped * treated with thrombolysis within 24hrs * any other reason the investigator deems the subject to be unsuitable for the study e.g., active malignant tumor * concomitant therapy with strong cyp3a inhibitors, cyp3a substrates with narrow therapeutic index, or strong cyp3a inducers * any life-threatening condition with life expectancy less than 6months * mental condition (dementia, alcohol or drug abuse) which may be affect study compliance or prevent understanding of the aims, investigational procedures or possible consequences of the study * high risk due to malignant hypertension * the conditions associated with increased risk of bradycardiac events * subjects with severe liver disease * subjects requiring dialysis * increased bleeding risk * history of cerebral hemorrhage, gastrointestinal bleeding within 6months, major surgical procedure within 30days * thrombocytopenia or leukopenia * positive pregnancy test or is known to be pregnant

Keywords: acute coronary syndrome coronary disease coronary artery disease
intraoperative epiaortic scanning for preventing early stroke after off-pump coronary artery bypass

Conditions: Coronary Artery Occlusive Disease

Summary: recently epiaortic ultrasound scanning (eas) has been recommended as an intraoperative tool to accurately assess ascending aorta disease. to date, several studies have reported that eas is superior to tee and surgical palpation


Eligibility criteria:
inclusion criteria: patients underwent who isolated off-pump coronary artery bypass exclusion criteria: 1. combined carotid procedures 2. preoperative cerebral haemorrhage 3. nonoperative unstable vital signs such as ventricular fibrillation or cardiac arrest
targeting cd19/cd20/cd22 triple-targeted cell in patients with relapsed/refractory b-cell lymphoma

Conditions: B-cell Lymphoma Recurrent; B-cell Lymphoma Refractory

Summary: a phase i, open-label clinical study to evaluate the safety, tolerability, and efficacy of lcar-aio, a triple-targeted cell preparation targeting cd19/cd20/cd22, in patients with relapsed/refractory b-cell lymphoma.

this is an open-label, dose-escalation/dose extension study to assess the safety, tolerability, and efficacy of lcar-aio in the patient ≥ 18 years of age with relapsed or refractory b cell lymphoma. subjects who meet the eligibility criteria will receive a single dose of lcar-aio injection. the study will include the following sequential phases: screening, pre-treatment (cell product preparation; lymphodepleting chemotherapy), treatment, and follow-up.

Eligibility criteria:
inclusion criteria: 1. subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures, and have signed informed consent. 2. aged 18-75 years (inclusive). 3. eastern cooperative oncology group (ecog) performance status of 0 or 1. 4. histologically confirmed b-cell lymphoma that expresses at least one of cd19/cd20/cd22. 5. at least one measurable tumor lesion determined according to lugano 2014 criteria. 6. response to prior therapy is consistent with one of the following: 1. primary refractory: it means that the best response to first-line therapy (at least 2 cycles) is pd, or best response to first-line therapy (at least 4 cycles) is sd but the duration is less than 6 months, which is considered to be pd; 2. relapsed or refractory after 2 or more lines of therapy. refractory is defined that best respond to the most recent treatment regimen (at least 2 cycles) is pd, or best response to the most recent treatment regimen (at least 4 cycles) is sd but the duration is less than 6 months, which is considered to be pd; 3. progression or relapse within 12 months after hematopoietic stem cell transplantation; if salvage therapy is applied after transplantation, the patient must be unresponsive or relapsed to the last line of therapy; 7. life expectancy≥ 3 months 8. clinical laboratory values meet screening visit criteria 9. adequate organ function; exclusion criteria: subject eligible for this study must not meet any of the following criteria: 1. prior antitumor therapy with insufficient washout period ; 2. patients who received dual-targeted car-t cell therapy (including but not limited to sequential infusion) at any time in the past, or who received car-t cell therapy of cameloid origin; 3. with acute or chronic graft-versus-host disease (gvhd); 4. patients who are positive for any index of hepatitis b surface antigen (hbsag), hepatitis b virus deoxyribonucleic acid (hbv dna), hepatitis c antibody (hcv-ab), hepatitis c virus ribonucleic acid (hcv rna), or human immunodeficiency virus antibody (hiv- ab). 5. known life-threatening allergies, hypersensitivity, or intolerance to lcar-aio car-t cell or its excipients, including dmso (refer to investigator's brochure). 6. pregnant or lactating women;
evaluation of chewing efficiency of conventional complete denture in comparison to reinforced poly amide denture

Conditions: Mouth, Edentulous

Summary: the trial is done in order to reinforce polyamide to improve its modulus of elasticity to be able to use it as a denture base material in all clinical cases


Eligibility criteria:
inclusion criteria: 1. male or female patient with age range (45-55) completely edentulous and in good medical condition. 2. all patients have skeletal angle's class i maxillo-mandibular relationship and have sufficient interarch distance. 3. free from any systemic or neuromuscular disorder that might affect chewing efficiency of masticatory muscles. 4. free from any tempro-mandibular joint disorder. 5. the patients have good oral hygiene. 6. the edentulous ridges should be covered by firm healthy mucosa. 7. healthy and co-operative patients. exclusion criteria: 1. patients with bad habits as severe clenching or bruxism, drug or alcohol addiction, moderate or heavy smoking (greater than 10 cigarettes per day). 2. previous history of radiotherapy or chemotherapy. 3. any skeletal problem dictates surgical intervention. 4. patients having hormonal disorders as diabetes, thyroid or parathyroid hormonal diseases were not included. 5. patient with xerostomia or excessive salivation. 6. no intraoral soft and hard tissue pathosis. 7. psychiatric problems.
a study of olaratumab (imc-3g3) in previously treated participants with unresectable and/or metastatic gastrointestinal stromal tumors

Conditions: Gastrointestinal Stromal Tumor (GIST)

Summary: the purpose of this study is to evaluate the tumor response of stable disease (sd), partial response (pr), or complete response (cr) \[according to response evaluation criteria in solid tumors version 1.1 (recist v1.1 criteria)\] at 12 weeks in participants with gastrointestinal stromal tumors (gist) harboring platelet-derived growth factor receptor alpha (pdgfrα) mutations and patients with gist not harboring pdgfrα mutations.


Eligibility criteria:
inclusion criteria: * participant has histologically or cytologically confirmed, unresectable and/or metastatic gist * participant has measurable disease * participant has documented objective progression following, or intolerance to, treatment with both imatinib and sunitinib * participant's eastern cooperative oncology group (ecog) performance status (ps) is 0 to 2 * participant has either: 1. prior results from growth factor receptor associated with tyrosine kinase activity (kit) and pdgfrα mutation analysis that meet analytical criteria as defined for the on-study analysis of these mutations and tumor tissue (from either primary or metastatic tumor) that can be submitted for analysis within 30 days after the first dose of study therapy; or 2. if prior results from kit and pdgfrα mutation analysis are not available or do not meet analytical criteria as above, then tumor tissue (from either primary or metastatic tumor) must be submitted for genotype testing at the latest 28 days prior to the first dose of study therapy * participant has adequate hematologic, hepatic, renal and coagulation function * women of childbearing potential and sexually active males must agree to use adequate contraception prior to study and for at least 12 weeks after the last dose of imc-3g3 * participant has a life expectancy of ≥ 3 months exclusion criteria: * participant has untreated central nervous system metastases, and as a result, is clinically unstable with regard to neurologic function * participant has a history of another primary cancer * participant has received any investigational therapy within 14 days prior to registration, or is currently enrolled in any other type of medical research * participant is receiving concurrent treatment with other anticancer therapy * participant has known human immunodeficiency virus (hiv) infection * participant has undergone major surgery within 28 days prior to registration * if female, participant is pregnant or breastfeeding